Cyclopharm Ltd

AU:CYC Australia Medical Distribution
Market Cap
$51.90 Million
AU$83.82 Million AUD
Market Cap Rank
#24584 Global
#507 in Australia
Share Price
AU$0.70
Change (1 day)
+3.73%
52-Week Range
AU$0.58 - AU$1.46
All Time High
AU$3.26
Categories
Companies in Australia Medical Distribution
About

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more

Cyclopharm Ltd (CYC) - Net Assets

Latest net assets as of June 2025: AU$36.10 Million AUD

Based on the latest financial reports, Cyclopharm Ltd (CYC) has net assets worth AU$36.10 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$55.91 Million) and total liabilities (AU$19.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$36.10 Million
% of Total Assets 64.56%
Annual Growth Rate 7.23%
5-Year Change 149.65%
10-Year Change 226.13%
Growth Volatility 59.35

Cyclopharm Ltd - Net Assets Trend (2005–2024)

This chart illustrates how Cyclopharm Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cyclopharm Ltd (2005–2024)

The table below shows the annual net assets of Cyclopharm Ltd from 2005 to 2024.

Year Net Assets Change
2024-12-31 AU$42.73 Million +32.46%
2023-12-31 AU$32.26 Million -11.71%
2022-12-31 AU$36.54 Million -15.16%
2021-12-31 AU$43.07 Million +151.62%
2020-12-31 AU$17.12 Million -26.24%
2019-12-31 AU$23.20 Million +36.37%
2018-12-31 AU$17.02 Million -1.35%
2017-12-31 AU$17.25 Million +38.42%
2016-12-31 AU$12.46 Million -4.89%
2015-12-31 AU$13.10 Million +68.93%
2014-12-31 AU$7.76 Million +111.81%
2013-12-31 AU$3.66 Million -76.54%
2012-12-31 AU$15.61 Million +6.87%
2011-12-31 AU$14.60 Million +6.09%
2010-12-31 AU$13.77 Million -1.17%
2009-12-31 AU$13.93 Million +6.69%
2008-12-31 AU$13.06 Million +77.82%
2007-12-31 AU$7.34 Million +1397.06%
2006-12-31 AU$-566.06K -104.99%
2005-12-31 AU$11.34 Million --

Equity Component Analysis

This analysis shows how different components contribute to Cyclopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4498412000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock AU$87.07 Million 203.78%
Other Comprehensive Income AU$3.51 Million 8.22%
Total Equity AU$42.73 Million 100.00%

Cyclopharm Ltd Competitors by Market Cap

The table below lists competitors of Cyclopharm Ltd ranked by their market capitalization.

Company Market Cap
Everfuel AS
OL:EFUEL
 		$24.34 Million
Chin Yang Ind
KO:003780
 		$24.34 Million
Pylon Public Company Limited
BK:PYLON
 		$24.36 Million
ONUR TEKNOLOJI
IS:ONRYT
 		$24.36 Million
Media Prima Bhd
KLSE:4502
 		$24.34 Million
Dagi Giyim Sanayi ve Ticaret AS
IS:DAGI
 		$24.33 Million
Tokens.com Corp.
OTCQB:XBOTF
 		$24.33 Million
Brazilian Critical Minerals Ltd
AU:BCM
 		$24.32 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cyclopharm Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 32,259,482 to 42,729,869, a change of 10,470,387 (32.5%).
  • Net loss of 13,197,618 reduced equity.
  • Share repurchases of 1,144,915 reduced equity.
  • New share issuances of 24,002,712 increased equity.
  • Other comprehensive income increased equity by 375,560.
  • Other factors increased equity by 434,648.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income AU$-13.20 Million -30.89%
Share Repurchases AU$1.14 Million -2.68%
Share Issuances AU$24.00 Million +56.17%
Other Comprehensive Income AU$375.56K +0.88%
Other Changes AU$434.65K +1.02%
Total Change AU$- 32.46%

Book Value vs Market Value Analysis

This analysis compares Cyclopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.67x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-12-31 AU$-0.02 AU$0.70 x
2007-12-31 AU$0.25 AU$0.70 x
2008-12-31 AU$0.43 AU$0.70 x
2009-12-31 AU$0.38 AU$0.70 x
2010-12-31 AU$0.37 AU$0.70 x
2011-12-31 AU$0.41 AU$0.70 x
2012-12-31 AU$0.34 AU$0.70 x
2013-12-31 AU$0.06 AU$0.70 x
2014-12-31 AU$0.13 AU$0.70 x
2015-12-31 AU$0.23 AU$0.70 x
2016-12-31 AU$0.22 AU$0.70 x
2017-12-31 AU$0.25 AU$0.70 x
2018-12-31 AU$0.25 AU$0.70 x
2019-12-31 AU$0.34 AU$0.70 x
2020-12-31 AU$0.22 AU$0.70 x
2021-12-31 AU$0.48 AU$0.70 x
2022-12-31 AU$0.40 AU$0.70 x
2023-12-31 AU$0.35 AU$0.70 x
2024-12-31 AU$0.42 AU$0.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cyclopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -30.89%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -47.87%
  • • Asset Turnover: 0.44x
  • • Equity Multiplier: 1.45x
  • Recent ROE (-30.89%) is below the historical average (-0.49%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 13.95% 17.34% 0.43x 1.85x AU$448.03K
2006 0.00% 19.63% 1.14x 0.00x AU$2.08 Million
2007 15.41% 10.17% 1.01x 1.50x AU$397.02K
2008 13.46% 16.14% 0.59x 1.42x AU$451.51K
2009 14.68% 15.59% 0.67x 1.41x AU$651.63K
2010 3.27% 4.76% 0.43x 1.61x AU$-926.51K
2011 -6.55% -9.27% 0.48x 1.46x AU$-2.42 Million
2012 -6.69% -9.72% 0.50x 1.39x AU$-2.60 Million
2013 -21.30% -6.56% 1.32x 2.46x AU$-1.15 Million
2014 52.42% 33.75% 1.10x 1.41x AU$3.29 Million
2015 36.58% 38.09% 0.76x 1.26x AU$3.48 Million
2016 7.15% 6.20% 0.88x 1.32x AU$-354.81K
2017 -8.84% -11.56% 0.56x 1.36x AU$-3.25 Million
2018 -0.21% -0.26% 0.57x 1.38x AU$-1.74 Million
2019 -12.55% -20.69% 0.43x 1.40x AU$-5.23 Million
2020 -35.31% -41.18% 0.52x 1.65x AU$-7.76 Million
2021 -11.70% -28.47% 0.32x 1.29x AU$-9.35 Million
2022 -18.10% -28.47% 0.47x 1.36x AU$-10.27 Million
2023 -14.57% -17.85% 0.57x 1.42x AU$-7.93 Million
2024 -30.89% -47.87% 0.44x 1.45x AU$-17.47 Million

Industry Comparison

This section compares Cyclopharm Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

  • Industry: Medical Distribution
  • Average net assets among peers: $54,430,634
  • Average return on equity (ROE) among peers: 16.56%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cyclopharm Ltd (CYC) AU$36.10 Million 13.95% 0.55x $24.34 Million
Ebos Group Ltd (EBO) $54.43 Million 16.56% 1.19x $2.17 Billion